“An Extra Variable to Consider”—Vaccine-Induced Seropositivity and Adolescent HIV Vaccine Clinical Trials
| dc.contributor.author | Fatola, Omolayo | |
| dc.contributor.author | Corneli, Amy | |
| dc.contributor.author | Perry, Brian | |
| dc.contributor.author | Hanlen-Rosado, Emily | |
| dc.contributor.author | Nsonwu, Adora | |
| dc.contributor.author | Constantine, Evangelia P. | |
| dc.contributor.author | Thompson, Amelia B. | |
| dc.contributor.department | Medicine, School of Medicine | |
| dc.date.accessioned | 2023-10-31T14:23:38Z | |
| dc.date.available | 2023-10-31T14:23:38Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | Our study explores the understanding of vaccine-induced seropositivity (VISP) and its potential impact on US adolescents' and caregivers' willingness to participate in adolescent HIV vaccine clinical trials. Findings from in-depth interviews suggest that addressing concerns about VISP will be essential for future pediatric HIV vaccine trials in the United States. | |
| dc.eprint.version | Final published version | |
| dc.identifier.citation | Fatola O, Corneli A, Perry B, et al. "An Extra Variable to Consider"-Vaccine-Induced Seropositivity and Adolescent HIV Vaccine Clinical Trials. J Pediatric Infect Dis Soc. 2022;11(5):221-224. doi:10.1093/jpids/piac001 | |
| dc.identifier.uri | https://hdl.handle.net/1805/36810 | |
| dc.language.iso | en_US | |
| dc.publisher | Oxford University Press | |
| dc.relation.isversionof | 10.1093/jpids/piac001 | |
| dc.relation.journal | Journal of the Pediatric Infectious Diseases Society | |
| dc.rights | Publisher Policy | |
| dc.source | PMC | |
| dc.subject | Adolescent | |
| dc.subject | HIV | |
| dc.subject | Prevention | |
| dc.subject | Vaccine-induced seropositivity (VISP) | |
| dc.title | “An Extra Variable to Consider”—Vaccine-Induced Seropositivity and Adolescent HIV Vaccine Clinical Trials | |
| dc.type | Article | |
| ul.alternative.fulltext | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155599/ |